Evidence map›Paper›PMID 37306910›Full record

ArticleCancer treatment and research2023

Targeted Therapy and Personalized Medicine.

Rida Fatima Saeed, Uzma Azeem Awan, Sidra Saeed, Sara Mumtaz, Nosheen Akhtar, Shaista Aslam

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer treatment and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
78.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Bioinspired functional materials for biomedical applications.Frontiers in bioengineering and biotechnology · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Rida Fatima SaeedDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan. rida.saeed@numspak.edu.pk.ORCID http://orcid.org/0000-0003-1577-1062
Uzma Azeem AwanDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
Sidra SaeedUniversity Centre Leeds, Leeds, UK.
Sara MumtazDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
Nosheen AkhtarDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
Shaista AslamDepartment of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.
National University of Medical Sciences · PKUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted therapy and personalized medicine are novel emerging disciplines of cancer research intended for treatment and prevention. One of the most significant advancements in modern oncology is the shift from an organ-centric strategy to a personalized strategy guided by deep molecular analysis. This shift in view, which focuses on the tumour's precise molecular changes, has paved the way for individualized treatment. Researchers and clinicians are using targeted therapies to select the best treatment available based on the molecular characterization of malignant cancer. In the treatment of a cancer, personalized medicine entails the use of genetic, immunological, and proteomic profiling to provide therapeutic alternatives as well as prognostic information about cancer. In this book, targeted therapies and personalized medicine have been covered for specific malignancies, including latest FDA-approved targeted therapies and it also sheds light on effective anti-cancer regimens and drug resistance. This will help to enhance our ability to conduct individualized health planning, make early diagnoses, and choose optimal medications for each cancer patient with predictable side effects and outcomes in a quickly evolving era. Various applications and tools' capacity have been improved for early diagnosis of cancer and the growing number of clinical trials that choose specific molecular targets reflects this predicament. Nevertheless, there are several limitations that must need to be addressed. Hence, in this chapter, we will discuss recent advancements, challenges, and opportunities in personalized medicine for various cancers, with a specific emphasis on target therapies in diagnostics and therapeutics.

Indexed as

Drug-Related Side Effects and Adverse ReactionsPrecision MedicineHealth PlanningHumansMedical OncologyProteomicsUnited StatesCancer biomarkerCancer treatmentDrug developmentPersonalized medicinePrecision medicineTargeted therapy

Identifiers

PMID37306910
OpenAlexW4380291476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.